SciSparc Ltd. (SPRC): BCG Matrix [Dec-2025 Updated]

You're assessing SciSparc Ltd. (SPRC) through the BCG lens, and honestly, the picture is what you'd expect for a clinical-stage firm: it's a tough spot dominated by 'Dogs' and 'Question Marks.' Given the net loss of $9.33 million through H1 2025 against only $0.461 million in revenue, there are no 'Cash Cows' to fund the fight, and certainly no 'Stars' yet. The entire near-term value hinges on turning those high-investment, high-uncertainty pipeline assets-the Question Marks-into future winners, while the low-return consumer sales are clearly in the 'Dog' category. Let's break down exactly where every piece of the SciSparc Ltd. (SPRC) portfolio lands below.

Background of SciSparc Ltd. (SPRC)

You're looking at SciSparc Ltd. (SPRC), and honestly, the story here is one of a clinical-stage pharmaceutical company trying to navigate a complex path in the cannabinoid therapy space. SciSparc Ltd. is based in Tel Aviv, Israel, and its main focus is developing drugs based on cannabinoid molecules, specifically targeting disorders of the central nervous system. That's the core of their operation.

The company has a portfolio of drug candidates they are pushing through development. You've got SCI-110, which they are testing for Tourette syndrome and agitation related to Alzheimer's disease. Then there's SCI-210, aimed at treating autism spectrum disorder and status epilepticus. They also have CannAmide, which is positioned as a solution for chronic pain and inflammation. To be fair, they also run a second, smaller segment: the online sale of various hemp-derived consumer products, like hemp gummies and creams.

The year 2025 has been marked by significant structural changes. For instance, SciSparc Ltd. executed a one-for-twenty-one reverse share split effective July 3, 2025, which dramatically reduced the number of outstanding shares from about 11.2 million to roughly 534,600. Plus, in a major strategic move in October 2025, the company entered an agreement to transfer its advanced clinical-stage pharmaceutical portfolio into Miza III Ventures (TSXV: MIZA. P), valuing those assets at approximately US$11.6M.

Looking at the financials reported through mid-2025, the picture is tough. For the half-year ended June 30, 2025, sales came in at just USD 0.461 million, which was down from the USD 0.84 million reported in the same period the prior year. That period also saw the net loss widen to USD 9.33 million, up from a loss of USD 3.44 million a year earlier. However, the trailing twelve-month revenue, as of September 30, 2025, was reported at $1.31M, showing a significant year-over-year increase of 187.98% from the prior year's comparable period. As of late August 2025, the company's market capitalization stood at $1.62M.

The stock market sentiment, as of early December 2025, reflected some of this uncertainty; one forecast indicated a bearish sentiment, with the stock trading around $1.71 as of December 3, 2025. You'll want to keep an eye on the progress of SCI-110, as its Phase IIb trial advancement remains a key operational focus for SciSparc Ltd.

SciSparc Ltd. (SPRC) - BCG Matrix: Stars

For SciSparc Ltd. (SPRC), the definition of a 'Star'-a product with high market share in a high-growth market-is not currently met by any commercialized product. The company's core portfolio remains pre-commercial, meaning it lacks established market dominance to qualify for this quadrant based on current sales figures. As of the interim financial statements for H1 2025, the trailing 12-month revenue was $927K as of June 30, 2025, which is indicative of a pre-revenue or early-stage commercial entity, not a market leader.

The asset that most closely aligns with the potential for a Star position is SCI-110 for Tourette Syndrome (TS). This investigational drug candidate is targeting a market segment that exhibits the high-growth characteristic required for a Star. The Tourette Syndrome Treatment Market size stood at USD 2.71 billion in 2025 and is projected to reach USD 3.48 billion by 2030, reflecting a Compound Annual Growth Rate (CAGR) of 5.12%. This growth is sustained by factors like earlier diagnosis and clinical adoption of newer drug classes.

The current market structure for TS treatment highlights the competitive landscape SCI-110 would enter. In 2024, antipsychotics held a dominant 58.54% share of the market revenue. To become a Star, SCI-110 would need to capture a significant portion of this market share as it grows.

SCI-110 is currently classified as high-risk because it is still in clinical development, despite achieving a significant regulatory milestone. The U.S. Food and Drug Administration (FDA) confirmed the Investigational New Drug (IND) application for its Phase IIb clinical trials in adults with TS, with the IND confirmation occurring on September 30, 2024. The trial aims to evaluate efficacy, safety, and tolerability in patients aged 18 to 65 years. If the Phase IIb trial yields successful results, the asset transitions from a high-risk Question Mark toward a potential Star, given the high-growth nature of the CNS disorder market it targets.

The company's strategic reality reflects this pipeline focus, as evidenced by its financial structure. SciSparc Ltd. reported a Negative shareholders equity as of November 20, 2025, and its Research & Development spend for the full year 2024 was -1.7m USD. This cash burn is typical for a specialty clinical-stage pharmaceutical company focused on development rather than current market sales.

The strategic focus for SciSparc Ltd. is clearly on cultivating these future Stars through its clinical pipeline, rather than defending existing market share. The company's activities, such as the Phase IIb trial for SCI-110, are investments designed to create future market leaders. The company has no analyst forecast covering revenue or earnings growth, which is a rare situation for 97% of covered companies, underscoring the pre-commercial nature of its operations.

Key pipeline milestones relevant to potential Star status include:

• SCI-110 for Tourette Syndrome is in Phase IIb clinical trial.
• The IND for the Phase IIb trial was cleared by the FDA.
• SCI-110 for Alzheimer's disease has completed its Phase II clinical trial.
• SCI-210 for autism commenced a randomized, double-blind, placebo-controlled trial in Q1 2024.

SciSparc Ltd. (SPRC) - BCG Matrix: Cash Cows

When we map SciSparc Ltd. (SPRC) onto the Boston Consulting Group (BCG) Matrix, the Cash Cow quadrant-reserved for high market share, low growth businesses that generate excess cash-is demonstrably empty. Honestly, you won't find any product or business unit here generating the stable, significant cash flow needed to fund the rest of the operation. That role, in a healthy company, is critical; for SciSparc Ltd., the financial reality points elsewhere.

The primary indicator against any Cash Cow status is the company's recent profitability, or lack thereof. For the half year ended June 30, 2025, SciSparc Ltd. reported a net loss of $9.33 million. A true Cash Cow generates surplus cash; this figure clearly signals a significant cash burn, placing any asset in the Question Mark or Dog category, not the Cash Cow quadrant.

Furthermore, the top-line performance does not support the profile of a mature market leader. Revenue from all sources for the first half of 2025 totaled only $0.461 million. This level of sales is far from being a sustainable generator of excess cash; in fact, it is insufficient to cover the operational losses incurred during the same period.

Here's a quick look at how the H1 2025 performance compares to the prior year, which helps frame the current cash consumption:

The comparison shows that not only is the revenue base small, but the net loss has widened substantially year-over-year, moving from a loss of $3.44 million to $9.33 million. This trend directly contradicts the high-profit margin expectation of a Cash Cow.

Given this financial structure, the strategic imperative for SciSparc Ltd. is clear, and it involves the opposite of milking a mature asset. The focus must be on survival and future development, not passive income distribution. You can see this reflected in the financial priorities:

• Cash preservation is the immediate operational goal.
• Funding is directed toward strategic investment, likely R&D.
• There is no excess cash available for shareholder dividends.
• The current state requires capital infusion, not distribution from a mature line.

To be fair, the company's activity in the biotechnology sector suggests most, if not all, current assets are likely positioned as Question Marks-high growth potential but requiring heavy investment and not yet profitable-or Dogs, if their development paths have stalled. The financial data confirms that SciSparc Ltd. is currently consuming cash at a high rate, making the Cash Cow designation inapplicable for any of its current operations as of the latest reporting period.

SciSparc Ltd. (SPRC) - BCG Matrix: Dogs

You're looking at the parts of SciSparc Ltd. (SPRC) that require management attention because they operate in low-growth areas and don't command a significant market share. These are the Dogs in the portfolio, units that tie up capital without delivering substantial returns.

The consumer-facing side, specifically the hemp seed oil-based products sold through the subsidiary on Amazon, fits this profile. This segment is clearly not a core value driver for the specialty pharmaceutical focus of SciSparc Ltd. (SPRC). The financial data from the first half of 2025 shows the scale of this non-core operation.

Here's a quick look at the sales trend for the period ending June 30, 2025, compared to the prior year:

That drop in sales from H1 2024 to H1 2025 suggests the market share or growth rate for this unit is indeed low, consistent with a Dog classification. Expensive turn-around plans usually don't help here; the strategy is typically minimization or exit.

The recent divestiture of the majority-owned subsidiary, MitoCareX, serves as a textbook example of exiting a Dog, even if the asset was previously considered a Question Mark. SciSparc Ltd. (SPRC) monetized this non-core asset in October 2025.

• Cash received by SciSparc Ltd. (SPRC) for the sale of 6,622 MitoCareX shares was \$700,000.
• The transaction closed around October 20/23, 2025.
• Sellers, including SciSparc Ltd. (SPRC), also received stock equating to 40% of N2OFF's fully diluted capital.
• Sellers are entitled to 30% of N2OFF's financing proceeds, capped at \$1.6 million, over five years.

To be fair, the equity upside provides a contingent return, but the immediate cash realization of \$700,000 for a majority stake highlights the low-return nature of the asset being shed. Honestly, this move signals a clear intent to stop tying up capital in non-core ventures.

The entire pre-2025 corporate structure and non-core assets that were spun off or sold are essentially Dogs. They required capital without a clear path to the high returns seen in the core pharmaceutical development pipeline. You can see the overall financial pressure this created:

• Net loss for H1 2025 was \$9.33 million.
• Net loss for H1 2024 was \$3.44 million.
• Diluted loss per share from continuing operations for H1 2025 was \$17.92.

Finance: draft 13-week cash view by Friday.

SciSparc Ltd. (SPRC) - BCG Matrix: Question Marks

You're looking at the assets that require significant capital infusion right now, hoping they become the next big thing. For SciSparc Ltd., these Question Marks are heavily weighted toward its pharmaceutical pipeline and a recent strategic technology bet.

The most significant Question Mark component involves the advanced clinical-stage pharmaceutical portfolio. This portfolio, which includes assets like SCI-160 and SCI-210, was transferred to its majority-owned subsidiary, Neurothera Labs (NTLX), in a transaction effective October 22, 2025. The value assigned to these transferred Target Assets was approximately US$11.6 million (or approximately CAD 15.8 million). This transfer itself is a strategy to focus R&D cash burn under a separate entity, though SciSparc retains a controlling stake of approximately 75%, potentially rising to approximately 84%.

The specific drug candidates within this group demand heavy investment with uncertain regulatory outcomes, which is the hallmark of a Question Mark. SCI-160, a proprietary synthetic CB2 receptor agonist for pain, remains in the pre-clinical stage of development. Meanwhile, SCI-210, targeting Autism Spectrum Disorder (ASD) and Status Epilepticus, was in a randomized, double-blind, placebo-controlled clinical trial involving 60 children aged 5 to 18, with a 20-week treatment period. These early/mid-stage trials consume cash without guaranteed returns.

A high-risk, high-reward bet that fits this quadrant is the non-binding term sheet signed on December 2, 2025, for NeuroThera Labs to acquire a 55% equity interest in an Israeli quantum computing bio data company. This move is designed to gain market share in a new, high-growth tech area by leveraging quantum-enabled clinical analytics, offering potential future Star status if successful, but requiring substantial initial investment and due diligence completion.

The financial reality of funding these high-potential but unproven assets is evident in the interim results. SciSparc Ltd. reported a net loss of USD 9.33 million for the half year ended June 30, 2025, a significant increase from the USD 3.44 million loss reported in the same period the prior year. This heavy investment is reflected in the sales figures for H1 2025, which were only USD 0.461 million, down from USD 0.84 million a year ago.

The commercialized product, CannAmide, an anti-inflammatory and chronic pain solution, is also categorized here because, despite being available in tablet form with a 400mg active pharmaceutical ingredient and holding a Health Canada product license, it likely has a low market share relative to established competitors, necessitating significant marketing spend to gain traction.

Here's a quick look at the key Question Mark assets and their associated figures:

The strategy for these Question Marks centers on rapid market share gain or divestment. SciSparc Ltd. is currently betting on heavy investment, as seen by the commitment to the quantum computing venture and the continued funding of the clinical pipeline, aiming to convert these cash-consuming units into Stars.

• The clinical trial for SCI-210 involved a 20-week treatment program.
• SciSparc's stake in Neurothera Labs is approximately 75% post-closing.
• H1 2025 sales were USD 0.461 million.
• The quantum computing acquisition consideration involves issuing shares equal to 40% of NeuroThera's non-diluted share capital.

Finance: review the cash burn rate for the NTLX subsidiary against the Q3 2025 burn rate by next Tuesday.